Over three days mir|detect the test at the company's own exhibition stand M371 at the congress of the German Society of Urology and was available to answer interested questions.
Prof. Dr Klaus-Peter Dieckmann shared his latest findings on miRNA-371a with colleagues as part of the scientific programme.
The mir|detect GmbH based in Bremerhaven, Germany, develops and produces nucleic acid-based in-vitro diagnostics for the early detection and aftercare of cancer. The CE-IVD-certified flagship product, the M371-Testenables the high-precision diagnosis and monitoring of testicular germ cell tumours. Based on the patented and innovative panta|Q® Technology mir|detect is working on a new generation of liquid biopsy tests.
Contact:
mir|detect GmbH
Fischkai 1 - 27572 Bremerhaven
E-Mail: info@mirdetect.deWeb: www.mirdetect.de
Copyright by me|detect & 21HAVN
